A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to produce defence proteins, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination in the third trimester still provides significant infant protection
Strong evidence from the latest research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme undertaken in England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that half-year window, providing robust and representative data of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scope of this study gives healthcare professionals and prospective parents with trust in the vaccine’s established performance across diverse populations and circumstances.
The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers did not receive the vaccination. This clear distinction highlights the vaccine’s critical role in protecting against serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology measured real-world outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when given across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for affected infants to breathe and feed properly. Parents commonly see their babies struggling visibly, their chests rising whilst they work to get adequate oxygen into their damaged lungs. Whilst most newborns get better with clinical support, a modest yet notable number die from RSV-related complications annually, making prevention through vaccination a critical public health imperative for defending the most vulnerable and youngest people in our communities.
- RSV produces lung inflammation, resulting in severe breathing difficulties in infants
- Nearly 50% of newborns contract the infection in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV each year
- Small numbers of infants die from RSV related complications annually in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to reach pregnant women
- Inconsistencies across regions in vaccine uptake rates throughout England demand focused enhancement
- Local healthcare systems adapting programmes to meet local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this preventative solution, the 80% reduction in admissions represents thousands of infants protected against severe infection. Parents no longer face the distressing scenario of seeing their babies labour to breathe or difficulty feeding, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, providing expectant mothers a proactive tool to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose severe RSV infection resulted in devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s advocacy for the jab emphasises the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to women in pregnancy in their third trimester, transforming what was once an inevitable seasonal threat into a manageable health risk.